Literature DB >> 2817594

Effect of cystic fibrosis on inhaled aerosol boluses.

P J Anderson1, J D Blanchard, J D Brain, H A Feldman, J J McNamara, J Heyder.   

Abstract

An aerosol bolus undergoes changes in shape between its inspiration and expiration. In comparison with the inhaled bolus, the exhaled bolus is more spread because of convective mixing, may have a shift in the location of the mode caused by asymmetries of filling and emptying of lung units, and contains fewer particles because of particle deposition. We hypothesized that the extent of these changes is related to lung health. To examine this, 11 patients with cystic fibrosis (CF) and 11 healthy subjects inhaled 70 cm3 boluses containing 1 micron monodisperse particles that were inspired to volumetric penetrations (Vp) of 100 to 700 cm3. As each bolus was expired, we measured spreading (volumetric width at one-half aerosol concentration peak height), modal shift, and particle deposition. Patients with CF exhaled boluses that were broader than those exhaled by normal subjects at all penetrations examined. At a Vp of 600 cm3, patients had a mean bolus half-width that was 68% greater than that of healthy subjects (p less than 0.0001), and they exhaled the bolus mode 20% earlier (p less than 0.0002). Particle deposition was increased compared with that in normal subjects at all Vp. For example, mean deposition at a Vp of 600 cm3 was 46.2 +/- 2.6% (SE) for the patients versus 25.8 +/- 1.6% for the normal subjects (p less than 0.0001). Among the patients with CF, pulmonary function parameters indicating obstruction were significantly correlated with bolus spreading and aerosol deposition: the percent predicted FEV1/FVC was inversely correlated with spreading (r = -0.88, p less than 0.0004) and deposition (r = -0.84, p less than 0.0008).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2817594     DOI: 10.1164/ajrccm/140.5.1317

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  9 in total

Review 1.  Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications.

Authors:  N R Labiris; M B Dolovich
Journal:  Br J Clin Pharmacol       Date:  2003-12       Impact factor: 4.335

Review 2.  Aerosol deposition in health and disease.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2012-06       Impact factor: 2.849

3.  Total and regional deposition of inhaled aerosols in supine healthy subjects and subjects with mild-to-moderate COPD.

Authors:  Chantal Darquenne; Wayne J Lamm; Janelle M Fine; Richard A Corley; Robb W Glenny
Journal:  J Aerosol Sci       Date:  2016-04-30       Impact factor: 3.433

4.  Theoretical diagnosis of emphysema by aerosol bolus inhalation.

Authors:  Robert Sturm
Journal:  Ann Transl Med       Date:  2017-04

Review 5.  Studies using radiolabelled aerosols in children.

Authors:  M L Everard
Journal:  Thorax       Date:  1994-12       Impact factor: 9.139

6.  Aerosol bolus dispersion in healthy and asthmatic children-theoretical and experimental results.

Authors:  Robert Sturm
Journal:  Ann Transl Med       Date:  2014-05

7.  Aerosol deposition as a function of airway disease: cystic fibrosis.

Authors:  T Martonen; I Katz; W Cress
Journal:  Pharm Res       Date:  1995-01       Impact factor: 4.200

Review 8.  Aerosol deposition in the human lung in reduced gravity.

Authors:  Chantal Darquenne
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2014-06       Impact factor: 2.849

Review 9.  Inhalation delivery technology for genome-editing of respiratory diseases.

Authors:  Michael Y T Chow; Rachel Yoon Kyung Chang; Hak-Kim Chan
Journal:  Adv Drug Deliv Rev       Date:  2020-06-05       Impact factor: 15.470

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.